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health states based on visual acuity (VA): >20/40, 20/40 to
>20/80, 20/80 to >20/200, 20/200 to >20/400, and >20/400. The
model incorporates patients across all lesion subtypes: predom-
inately classic, minimally classic, and occult. All drug and pro-
cedure costs were derived from US published sources, including
Medicare Part B Drugs Average Sales Price and RBRVS. Expert
interviews were conducted to determine adverse events treatment
patterns and vision rehabilitation resource use. Relative risks and
costs associated with effects associated with declining VA
(depression, bone fractures, skilled nursing facilities, and nursing
homes) were extracted from a Medicare analysis. Transition
probabilities were derived from published trial data for both
products for each of the 3-month cycles. Utilities were derived
from similar published sources as previous AMD models. Results
are expressed as vision years, quality-adjusted life years
(QALYs), medical costs and other costs, as well as the average
cost per vision year and QALY gained. RESULTS: For a lifetime
analysis the average cost per vision year was $20,459 for
Macugen and $26,079 for Visudyne and the average cost per
QALY was $19,609 for Macugen and $20,136 for PDT. A
patient treated with Macugen had on average 3.68 vision years
over a lifetime compared to 2.65 for a patient treated with Visu-
dyne. CONCLUSIONS: Macugen treatment produces more
years of sight than Visudyne for AMD treated patients. Macugen
is more cost-effective versus active treatment with Visudyne. A
limitation of the model is the absence of direct clinical compar-
ison between the products.
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OBJECTIVES: Many patients suffering from glaucoma ﬁnd it
necessary to use a second adjunctive topical agent to adequately
reduce the intraocular pressure (IOP). New more convenient
ﬁxed combination products containing two active anti-glaucoma
medications have been developed. The objective of this analysis
is to compare the cost of brimonidine/timolol ﬁxed combination
(Combigan®) with concomitant administration of brimonidine
(Alphagan®) and timolol, dorzolamide/timolol ﬁxed combina-
tion (Cosopt®), and concomitant administration of dorzolamide
(Trusopt®) and timolol. METHODS: RCTs have documented
equivalent safety and efﬁcacy in terms of IOP control of combi-
nation products in comparison with their individual components
(Sall et al., 2003; Solish et al., 2004). A cost-minimization analy-
sis including drug costs and visits at the ophthalmologist was
carried out for UK and other European counties with both a
health care and drug alone perspective. An RCT (Simmons et al.,
2001) has shown that Alphagan+timolol was more effective than
Trusopt+timolol in terms of patients achieving target IOP, there-
fore a cost-effectiveness analysis was constructed for this com-
parison. RESULTS: The 3-months health care costs analysis
(drug alone) in the UK using Combigan was £264.00 (£30.00)
compared with £268.11 (£34.11) for Alphagan+timolol and
£264.15 (£30.15) for Cosopt. With a 12-months perspective,
including additional drug and visits, the health care costs (drug
alone) rose to £510.00 (£120.00) for Combigan compared 
with £526.44 (£136.44) for Alphagan+timolol and £510.60
(£120.60) for Cosopt. The cost-effectiveness analysis docu-
mented that Alphagan was more cost-effective than Trusopt
adjunctively. CONCLUSION: Combigan provided better cost
value than Alphagan+timolol adjunctively. The use of Combigan
instead of Alphagan+timolol would result in annual societal
savings of around £728,000 in the UK. Combigan resulted in
slightly lower health care costs when modeling equal effective-
ness compared with Cosopt.
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OBJECTIVE: To compare the cost-effectiveness of early treat-
ment in disease progression of age-related macular degeneration
(AMD) to later treatment. A comprehensive model compares
starting treatment with Macugen (pegaptanib sodium), a new
treatment for AMD indicated for all patients with neovascular
AMD and standard care in patients with early disease progres-
sion (i.e., better visual acuity [VA]) versus late disease progres-
sion (i.e., worse VA). METHODS: A Markov framework was
used to model lifetime movement of an AMD cohort through
health states based on VA: >20/40, 20/40 to >20/80, 20/80 to
>20/200, 20/200 to >20/400, and >20/400. Drug and procedure
costs were derived from US published sources. Expert interviews
were conducted to determine adverse events treatment patterns
and vision rehabilitation resource use. Relative risks and costs
associated with effects associated with declining VA were
extracted from a Medicare analysis. Transition probabilities
were derived from published trial data for both products for each
of the 3-month cycles. Utilities were derived from similar pub-
lished sources as previous AMD models. Results are expressed
as vision years, quality-adjusted life years (QALYs), medical
costs, and other costs, as well as the incremental cost per vision
year and QALY gained. Three runs of the model were conducted
with cohorts of patients starting in one of the following health
states: 20/40 to >20/80; 20/80 to >20/200; and 20/200 to
>20/400. RESULTS: For lifetime analysis incremental cost-
effectiveness ratios (ICERs) per vision year gained were $19,744,
$23,377, and $58,512 and ICERs per QALY gained were
$46,911, $67,058, and $135,400 versus standard care for
patients started in the 20/40 to >20/80, 20/80 to >20/200, and
20/200 to >20/400 states, respectively. CONCLUSIONS: Treat-
ing patients early when presenting with AMD results in lower
ICERs than waiting to treat patients until their VA worsens. To
achieve maximum cost beneﬁts treatment should begin as soon
as possible.
PEY12
PHARMACOECONOMIC ANALYSIS OF LATANOPROST
VERSUS DORZOLAMIDE/TIMOLOL IN THE TREATMENT OF
OPEN-ANGLE GLAUCOMA IN SPAIN
Ortega P, Soto J, Fernández-Arias I, De Miguel V
Pﬁzer Spain, Alcobendas, Madrid, Spain
OBJECTIVE: To estimate the efﬁciency of latanoprost against
the ﬁxed-combination of dorzolamide/timolol in treating
patients with glaucoma in Spain. METHODS: A cost-minimiza-
tion analysis was carried out by building a decision analytical
model, because the effectiveness of both therapeutic options 
in lowering intraocular pressure (IOP) was similar in a per-
formed systematic review of the literature. However, dorzo-
lamide/timolol was associated with a higher incidence of adverse
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events and patient withdrawals. Health care resource utilization
was taken from published clinical trials measuring IOP-lowering
of alternatives under evaluation and a local expert panel. Only
direct medical costs were included in the model (drug acquisi-
tion, diagnostic procedures, ophthalmologist visits and treatment
of withdrawals as second-line therapy). Drug acquisition cost
data were obtained from ofﬁcial sources while the rest of costs
data were taken from a national health care costs database. The
perspective selected for this analysis was the Spanish National
Health Service and the time horizon chosen was for three
months, the time that patients were followed-up in most of the
reported clinical trials. RESULTS: Cost per patient associated
with the use of latanoprost was of €279 while the cost per patient
secondary to use dorzolamide/timolol was of €281, with an
incremental cost of €2 per patient treated. CONCLUSIONS:
Despite Latanoprost acquisition is bigger, it is a more cost-
effective alternative than the ﬁxed-combination of dorzo-
lamide/timolol because produces similar clinical results with
lower global associated costs. Therefore, latanoprost should be
a therapeutic option to choose rather than dorzolamide/timolol
in the treatment of open-angle glaucoma in Spain.
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OBJECTIVE: Endophthalmitis is the most severe infection fol-
lowing eye trauma (injury, surgery, injection, etc.). Medical costs
and visual loss consequences are compared here. METHODS: A
mailing announcing the creation of the National Endophtalmi-
tis Survey was sent to all French ophthalmologists. A total of
424 replies were received and 346 (82%) were positive. A stan-
dardized anonymous questionnaire collected information on the
operative conditions, endophthalmitis characteristics, treatments
and clinical outcomes. The economic point of view was that of
the French NHS and medical costs were extracted from the
national Diagnosis Related Group database. Utility related to
visual acuity loss was estimated from the literature (Brown). A
€50,000/QALY threshold was used to assess cost-effective social
value related to vision loss. A 5% discount rate was used.
RESULTS: Information on 88 cases of endophthalmitis was col-
lected. The mean age was 75.1 years and 44% were women. All
patients were hospitalized, had bacteriological samples, and were
treated with either systemic or intra-vitreal antibiotics. 25.3%
had a vitrectomy. Complications were reported in 23.1% and
most were mainly retinal detachments. 3 months after surgery,
29.4% of the eyes had a visual acuity (VA) less than 1/20 and in
57.4% VA was less than 5/10. The average endophthalmitis
medical cost was €4125. The loss in utility was 0.203 on average
(baseline VA ﬁxed at 8/10). With a life expectancy of 5 years,
the average discounted social value of endophthalmitis vision
loss was €46,000. CONCLUSION: The social value attributable
to vision loss subsequent to endophthalmitis is more than ten
times higher than its medical cost.
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OBJECTIVE: To evaluate the impact of best and worst eye visual
acuity (VA) on the consumption of medical and non medical
resources in patients with wet Age-Related Macular Degenera-
tion (AMD). METHODS: This study conducted in France,
Germany and Italy was cross-sectional with some data collected
retrospectively. Patients with an exudative AMD form were
included and were stratiﬁed into four levels of severity using two
VA thresholds, 20/200 for the worst eye (WE) and 20/40 for the
best eye (BE). In addition to demographics, AMD description
and VA data, the medical and non-medical resources used for
AMD reasons during the previous year were collected. Costs
were assessed for each country according to a global payer per-
spective. An analysis of variance was performed on cost variables
to estimate the impact of each eye adjusted by sex, age and
country. RESULTS: 360 patients were included with a majority
of females (60%). Mean age at inclusion was 77 years and time
since diagnosis 2.3 years. 27% of patients had BE >20/40 and
WE >20/200 and 25.5% BE <20/40 and WE <20/200. Total costs
were €3923.5 with 64.5% of medical costs and 35.5% of non-
medical costs. Total costs increased with the AMD severity with
a cost for the more severe group 1.5 times higher than for the
less severe group. Costs were mainly associated with the BE VA.
Medical cost was higher in France (€3714 versus €1900 on
average in Germany and Italy). It increased slightly between less
severe and more severe AMD. Non medical cost was signiﬁcantly
higher for patients with more severe disease and higher in 
Germany compared to the two other countries. CONCLUSION:
This study shows the high impact of AMD on costs and the pos-
itive correlation between costs and AMD severity. Non medical
costs of the most severe patients equaled medical costs.
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OBJECTIVE: To estimate the number of patients with endoph-
talmitis hospitalized in France, its average cost and hospital
ﬁnancing consequences. METHODS: The French PMSI (Pro-
gramme de Médicalisation des Systèmes d’Information) 2003
database was analysed. Patients with the following principal
diagnoses were extracted: “purulent endophthalmitis”, “other
endophthalmitis”, and “endophthalmitis associated with
another disease”. Two mean lengths of stay (LoS) were com-
pared: the overall patient sample and the DRG-weighted esti-
mate. Endophthalmitis costs were estimated as the sum of
weighted average DRG costs plus length of stay multiplied 
by hospital variable costs. RESULTS: 1681 endophthalmitis
cases were reported (age 66.7, 50% male). 1449 cases (86.2%)
were in the public sector and 2.8% were ward transfers. A 
total of 221 (13.1%) had a vitrectomy, the most common
endophtalmitis-related surgery. A total of 85 (5.1%) required a
ward transfer and 4 (0.2%) died. The patient LoS was 7.6 days
on average while the DRG weighted LoS was 4.3 days. Thus, the
PMSI underestimates endophtalmitis LoS by 3.3 days. Mean
